GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » Total Inventories
中文

BioPlus Acquisition (BioPlus Acquisition) Total Inventories : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is BioPlus Acquisition Total Inventories?

BioPlus Acquisition's total inventories for the quarter that ended in Jun. 2023 was $0.00 Mil. BioPlus Acquisition's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioPlus Acquisition's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-0.87.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


BioPlus Acquisition Total Inventories Historical Data

The historical data trend for BioPlus Acquisition's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition Total Inventories Chart

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
Total Inventories
- -

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioPlus Acquisition Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


BioPlus Acquisition  (NAS:BIOS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

BioPlus Acquisition's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

Net-Net Working Capital Per Share (Q: Jun. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.002+0.75 * 0+0.5 * 0-16.779
-0-0)/19.3675
=-0.87

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioPlus Acquisition's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioPlus Acquisition's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2023 ) / Average Total Inventories (Q: Jun. 2023 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioPlus Acquisition's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


BioPlus Acquisition Total Inventories Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000